Chelation Therapy: What It Is, How It Works, and What the Evidence Says

What Is Chelation Therapy?

The word “chelation” comes from the Greek word chele, meaning claw. It is an apt image. In chelation therapy, a chemical agent is introduced into the body that grabs onto metal ions, literally wrapping around them like a claw. Once bound, the metal-chelator complex becomes water-soluble and is filtered out through the kidneys and excreted in urine.

This is not alternative medicine in its origins. Chelation therapy has been a standard medical treatment since the 1950s, when it was first used to treat lead poisoning in factory workers and children exposed to lead paint. The FDA has approved several chelating agents for specific heavy metal poisonings, and these uses are well-established in mainstream toxicology (Hauptman et al., 2019).

Where things get more complicated, and more controversial, is in the off-label applications. Over the past few decades, chelation therapy has been promoted for cardiovascular disease, autism, chronic fatigue syndrome, and general “detoxification.” Some of these uses have real research behind them. Others rest on weak evidence and carry genuine risks. This guide will walk through all of it so you can make an informed assessment.

How Chelation Works in the Body

To understand chelation, you need to understand a bit about how metals behave in biological systems.

Heavy metals like lead, mercury, arsenic, and cadmium are toxic because they interfere with normal cellular processes. They can displace essential minerals from enzymes, generate oxidative stress, damage DNA, and disrupt cell signaling. The body has limited ability to clear these metals on its own. They accumulate in bones, organs, and soft tissues over time.

Chelating agents work through a straightforward chemical principle: they have a higher binding affinity for the target metal than the body’s own tissues do. When a chelating agent enters the bloodstream, it seeks out and binds the target metal, pulling it away from wherever it has lodged. The resulting chelate complex is stable, water-soluble, and small enough to pass through the kidneys into the urine.

The process is not perfectly selective. Chelating agents also bind essential minerals like calcium, zinc, iron, and magnesium to varying degrees. This is why mineral monitoring and supplementation are critical during chelation treatment. Without proper oversight, chelation can create dangerous mineral deficiencies (Flora & Pachauri, 2019).

FDA-Approved Uses of Chelation Therapy

Lead Poisoning

This is the most common and best-established use of chelation. Lead poisoning remains a serious public health concern, particularly in children living in older housing with lead paint and in workers exposed to lead in industrial settings.

The CDC recommends chelation therapy for children with blood lead levels at or above 45 mcg/dL. For adults, chelation is considered when blood lead levels are above 50 to 70 mcg/dL or when symptoms of lead toxicity are present. The primary agents used are calcium disodium EDTA (CaNa2EDTA) for IV administration and DMSA (succimer) for oral treatment in children (Hauptman et al., 2019).

Lead chelation is genuinely life-saving in acute poisoning cases. The evidence here is clear and uncontroversial.

Iron Overload

Patients with hereditary hemochromatosis, thalassemia major, or other conditions requiring repeated blood transfusions can accumulate dangerous levels of iron. Excess iron deposits in the heart, liver, and endocrine organs, causing progressive organ damage.

Deferoxamine (Desferal) has been the standard iron chelator for decades, given by slow subcutaneous or IV infusion. Newer oral iron chelators, deferasirox (Jadenu/Exjade) and deferiprone (Ferriprox), have improved convenience and quality of life for patients who need ongoing iron chelation (Saliba et al., 2019).

Wilson’s Disease

Wilson’s disease is a genetic disorder that causes copper to accumulate in the liver, brain, and other organs. Without treatment, it is fatal. Penicillamine (Cuprimine) and trientine (Syprine) are the chelating agents used to remove excess copper. These are taken orally on an ongoing basis, often for life. Zinc supplementation is also used to block copper absorption from food (European Association for the Study of the Liver, 2019).

Mercury and Arsenic Poisoning

Acute mercury poisoning (from inorganic or elemental mercury exposure) and arsenic poisoning are treated with chelation. DMSA and DMPS are the most commonly used agents for mercury. Dimercaprol (BAL, British Anti-Lewisite) is used for arsenic and can also be used for mercury, though it has more side effects. These are well-established toxicological treatments with clear medical indications (Rafati-Rahimzadeh et al., 2019).

Chelating Agents: A Closer Look

Not all chelating agents are the same. Each has different properties, targets, routes of administration, and risk profiles.

EDTA (Ethylenediaminetetraacetic Acid)

Two forms are used medically:

• Calcium disodium EDTA (CaNa2EDTA): The standard agent for lead poisoning. Given by IV infusion. Because it already contains calcium, it does not pull calcium from the body as aggressively.
• Disodium EDTA (Na2EDTA): Binds calcium strongly and has been associated with fatal hypocalcemia when administered too quickly. This is the form often used in off-label cardiovascular chelation. It requires very careful, slow IV infusion and cardiac monitoring.

EDTA binds a wide range of divalent and trivalent metal ions. It is poorly absorbed orally, so it is almost always given intravenously for therapeutic purposes.

DMSA (Succimer, Chemet)

DMSA is an oral chelating agent FDA-approved for lead poisoning in children. It is also used off-label for mercury chelation. It is generally considered safer than older agents because it has less tendency to redistribute metals within the body. It is well-absorbed orally and excreted through the kidneys (Bjorklund et al., 2019).

DMPS (Unithiol)

DMPS is used primarily for mercury and arsenic chelation. It is available in both oral and IV forms. It is widely used in Europe but does not have FDA approval in the United States, where it is available through compounding pharmacies. DMPS is water-soluble and does not cross the blood-brain barrier significantly, which means it primarily removes metals from the blood and extracellular spaces.

Deferoxamine (Desferal)

Specifically designed for iron chelation. Given by slow IV or subcutaneous infusion, often over 8 to 12 hours via a portable pump. Side effects include injection site reactions, visual and hearing changes with long-term use, and growth retardation in children at high doses.

Penicillamine (Cuprimine)

An oral chelator used primarily for Wilson’s disease (copper) and sometimes for lead and rheumatoid arthritis. It has a significant side effect profile including bone marrow suppression, kidney damage, and autoimmune reactions. Patients on penicillamine require regular blood and urine monitoring.

Off-Label Uses: Where the Controversy Lives

Cardiovascular Disease and the TACT Trial

The most significant and debated off-label application of chelation is for cardiovascular disease, particularly coronary artery disease and peripheral vascular disease. The theory is that EDTA chelation removes calcium from atherosclerotic plaques and reduces oxidative stress from toxic metals, thereby improving blood flow and reducing cardiovascular events.

This idea has been around since the 1950s, and for decades the medical establishment dismissed it as quackery. Then came TACT.

The Trial to Assess Chelation Therapy (TACT) was a large, NIH-funded, randomized, double-blind, placebo-controlled trial. It enrolled 1,708 patients aged 50 and older who had experienced a prior heart attack. Half received 40 IV infusions of disodium EDTA with vitamins; half received placebo infusions. The results, published in 2013, surprised many people (Lamas et al., 2013).

The chelation group showed an 18% reduction in the primary composite endpoint (death, heart attack, stroke, coronary revascularization, or hospitalization for angina) compared to placebo. This was statistically significant (p = 0.035). Even more striking, the subgroup with diabetes showed a 41% reduction in cardiovascular events and a 43% reduction in total mortality (Escolar et al., 2014).

These results were both promising and controversial. Critics pointed to the high dropout rate (about 17%), the modest overall effect size, and questions about blinding integrity. Supporters noted that the trial met its primary endpoint in a rigorous design and that the diabetes subgroup results were striking.

TACT2, a follow-up trial focused specifically on diabetic patients with prior heart attack, completed enrollment and results are anticipated to add clarity. The American Heart Association and American College of Cardiology have acknowledged TACT but have not changed treatment guidelines based on it (Lamas et al., 2018).

The bottom line on cardiovascular chelation: there is real data from a well-designed trial suggesting a benefit, particularly in diabetics. But it is a single trial, the effect is moderate, and the mechanism is not fully understood. It is reasonable to consider it, particularly for diabetic patients who have exhausted standard options, but it should not replace proven cardiovascular treatments.

Autism Spectrum Disorders

Some practitioners recommend chelation for children with autism based on the hypothesis that mercury or other heavy metal exposure contributes to autism spectrum conditions. This hypothesis has been largely discredited by mainstream research. Multiple large epidemiological studies have found no link between mercury-containing vaccines (thimerosal) and autism (Hviid et al., 2019).

The use of chelation for autism carries real risks (mineral depletion, kidney stress) without strong evidence of benefit. A child died in 2005 from cardiac arrest caused by hypocalcemia during EDTA chelation for autism, an event that prompted regulatory attention. The American Academy of Pediatrics does not recommend chelation for autism (Bauer et al., 2020).

If a child with autism is found to have documented heavy metal toxicity through validated testing, chelation under strict medical supervision could be warranted for the metal poisoning itself, but not as a treatment for autism.

Chronic Fatigue and “Detox”

Chelation is sometimes marketed for vague conditions like chronic fatigue, brain fog, or general “heavy metal detoxification.” While chronic low-level metal exposure can cause real symptoms, the diagnosis should be based on validated testing (blood and urine levels), not on unvalidated tests like hair mineral analysis or provoked urine tests.

Provoked urine testing, where a chelating agent is given and then urine metals are measured, is particularly problematic. The chelation agent pulls metals from tissues, making urine levels appear elevated. These post-provocation levels are then compared to normal reference ranges (established without provocation), inevitably showing “elevated” results. This can lead to unnecessary chelation treatment (Ruha et al., 2019).

IV vs. Oral Chelation

Chelation can be administered intravenously or orally, depending on the agent and the clinical situation.

IV Chelation

• Agents: CaNa2EDTA, Na2EDTA, deferoxamine, DMPS
• Duration: Each session lasts 1 to 3 hours (sometimes longer for EDTA)
• Frequency: Typically once or twice per week
• Setting: Medical office or infusion center
• Advantages: Higher bioavailability, more predictable dosing, medical monitoring during infusion
• Disadvantages: Time-consuming, requires clinic visits, IV access risks (infection, infiltration)

Oral Chelation

• Agents: DMSA, deferasirox, deferiprone, penicillamine
• Duration: Taken as capsules or tablets on a prescribed schedule
• Advantages: Convenient, can be done at home, less invasive
• Disadvantages: Lower or variable absorption for some agents, GI side effects, less direct medical oversight

Some over-the-counter supplements are marketed as oral chelators (modified citrus pectin, chlorella, cilantro extract, zeolite). These are not true chelating agents in the pharmacological sense. They may bind small amounts of metals in the gut, but they do not have the binding strength or systemic activity of pharmaceutical chelators. Their effectiveness for removing heavy metals from the body is not supported by strong evidence.

What Chelation Treatment Looks Like

If you are considering chelation therapy, here is what a typical course involves:

Initial evaluation: A thorough medical history, physical exam, and baseline laboratory testing. At a minimum, labs should include kidney function (BUN, creatinine, GFR), complete blood count, electrolytes (calcium, magnesium, zinc, iron), liver function, and validated heavy metal testing (blood and/or unprovoked urine).

Treatment sessions: For IV EDTA chelation, you sit in a recliner while the solution drips slowly over 1 to 3 hours. Vital signs are monitored. Many clinics offer multiple chairs so patients can receive treatment in a group setting. You can read, work on a laptop, or nap during the infusion.

Number of sessions: For lead poisoning, the number of sessions depends on the lead level and clinical response. For cardiovascular chelation (following the TACT protocol), 40 IV sessions are standard. Most off-label chelation protocols involve 20 to 40 sessions.

Frequency: Sessions are typically scheduled once or twice per week. Some aggressive protocols call for multiple sessions per week initially, then tapering.

Ongoing monitoring: Regular lab work during treatment is non-negotiable. This includes kidney function, complete blood count, and mineral levels. Any provider who does not order regular labs during chelation is cutting corners that could put your health at risk.

Supplementation: Because chelation removes essential minerals along with toxic metals, mineral supplementation is standard practice. This typically includes calcium, magnesium, zinc, and a full-spectrum mineral formula. Some protocols infuse minerals along with the chelating agent.

Risks and Side Effects

Chelation therapy is not benign. The risks are manageable when properly monitored but real when oversight is inadequate.

Common Side Effects

• Burning or discomfort at the IV site
• Nausea, vomiting, diarrhea
• Headache
• Fatigue
• Temporary drop in blood pressure
• Low-grade fever

Serious Risks

• Kidney damage: The kidneys must filter and excrete the metal-chelate complexes. Pre-existing kidney disease increases this risk. Kidney function must be monitored throughout treatment.
• Hypocalcemia: Disodium EDTA binds calcium aggressively. If infused too quickly, it can cause dangerously low blood calcium, leading to cardiac arrhythmias, seizures, and potentially death. This is the most dangerous acute risk of EDTA chelation.
• Essential mineral depletion: Zinc, iron, copper, and other essential minerals can be depleted, causing anemia, immune dysfunction, and other problems.
• Bone marrow suppression: Particularly with penicillamine and some other agents.
• Allergic reactions: Can occur with any chelating agent, though uncommon.
• Metal redistribution: Some chelators can mobilize metals from storage sites and redistribute them to more sensitive organs (particularly the brain) if the dosing protocol is not appropriate. This is a particular concern with DMPS and DMSA when used at high doses or in patients with high body burdens (Bjorklund et al., 2019).

Monitoring Requirements

Any responsible chelation protocol includes regular laboratory monitoring. Here is what should be tracked:

• Before starting: Complete blood count, comprehensive metabolic panel (including kidney and liver function), electrolytes, calcium, magnesium, zinc, iron studies, and baseline heavy metal levels.
• During treatment: Kidney function and minerals should be checked every 5 to 10 sessions or more frequently if abnormalities are found. Complete blood count should be monitored regularly.
• After completing treatment: Follow-up metal levels to confirm reduction, and monitoring of kidney function and minerals to ensure recovery.

A provider who skips these labs or dismisses the need for monitoring is not practicing safe medicine. Walk away.

Cost of Chelation Therapy

Chelation therapy costs vary depending on the setting, the agent used, and the geographic location:

• IV EDTA chelation: $100 to $300 per session. A full 40-session course costs $4,000 to $12,000.
• Oral DMSA: Less expensive per dose, but may require longer treatment courses.
• Initial evaluation and qEEG: $200 to $500 for the initial workup.
• Lab monitoring: Additional costs for regular blood work throughout treatment.

Insurance coverage depends entirely on the indication. Chelation for documented lead poisoning or iron overload is typically covered. Off-label cardiovascular chelation is almost never covered by insurance. Some patients use HSA or FSA funds for out-of-pocket chelation costs.

The TACT Trial: A Deeper Look

Because the TACT trial is the most significant piece of evidence for off-label chelation, it deserves a closer examination.

Study Design

• Randomized, double-blind, placebo-controlled, 2×2 factorial design
• 1,708 patients, age 50+, at least 6 weeks post-myocardial infarction
• 134 clinical sites across the US and Canada
• Funded by the National Center for Complementary and Integrative Health (NCCIH) and the National Heart, Lung, and Blood Institute (NHLBI)
• Treatment: 40 IV infusions of disodium EDTA plus ascorbic acid, B vitamins, and other nutrients, or matching placebo

Key Results

• Primary composite endpoint (death, MI, stroke, revascularization, hospitalization for angina): 26% in chelation group vs. 30% in placebo group (HR 0.82, p = 0.035)
• Pre-specified diabetes subgroup (n = 633): 25% in chelation vs. 38% in placebo (HR 0.61, p = 0.002)
• All-cause mortality in diabetic subgroup: 10% chelation vs. 16% placebo (HR 0.57, p = 0.011)

Criticisms and Limitations

• High dropout rate (approximately 17%)
• Questions about whether blinding was truly maintained (the chelation solution has a slight yellow tint)
• Single trial; replication is needed
• Complex intervention (EDTA plus high-dose vitamins) makes it hard to isolate the active component
• Some original data quality concerns at a small number of sites

Why Diabetics May Benefit More

The strongest hypothesis involves toxic metals and diabetic vasculopathy. Diabetic patients accumulate more cadmium and lead in their vasculature, and these metals contribute to oxidative stress and endothelial damage. Removing these metals via chelation may provide disproportionate benefit in this population. Another possibility is that EDTA’s ability to bind transition metals reduces catalytic free radical production, which is particularly damaging in the diabetic vascular environment (Escolar et al., 2014).

How to Evaluate Chelation Claims

Because chelation therapy exists in a space where legitimate medicine overlaps with aggressive marketing, here are some guidelines for evaluating claims:

Legitimate Indicators

• The provider orders validated baseline testing (blood or unprovoked urine metals)
• Clear medical indication for chelation (documented metal toxicity or, for cardiovascular use, reference to TACT data with honest discussion of limitations)
• Regular lab monitoring throughout treatment
• Mineral supplementation protocol
• Honest discussion of risks and limitations
• The provider has medical credentials and training in chelation

Warning Signs

• Diagnosis based solely on provoked urine testing
• Claims that chelation treats or cures a wide range of unrelated conditions
• No monitoring labs ordered during treatment
• Pressure to purchase large treatment packages upfront
• Use of unvalidated “detox” products marketed as chelation
• Claims that chelation is “completely safe” with no risks
• Diagnosing heavy metal toxicity based on hair analysis alone

Finding a Qualified Provider

If you decide chelation therapy is worth exploring, finding the right provider is essential.

ACAM (American College for Advancement in Medicine)

ACAM is the primary professional organization for physicians practicing chelation therapy, particularly for cardiovascular applications. ACAM-trained physicians have completed specific training in chelation protocols, safety monitoring, and patient selection. The ACAM website has a provider directory searchable by location (acam.org).

What to Look for in a Provider

• Medical degree (MD or DO) with active license
• Specific training in chelation therapy (ACAM training or equivalent)
• Follows the ACAM/TACT protocol for cardiovascular chelation
• Orders appropriate baseline and monitoring labs
• Has emergency protocols in place (particularly for hypocalcemia)
• Is transparent about the evidence base and limitations
• Does not make exaggerated claims

Questions to Ask

• What specific chelating agent do you use, and why?
• What lab work do you order before and during treatment?
• How do you monitor kidney function?
• What is your protocol for mineral replacement?
• How many chelation patients have you treated?
• What emergency medications and equipment do you have on site?
• How do you determine when treatment is complete?

The Controversy: An Honest Assessment

Chelation therapy sits at an unusual intersection in medicine. Its approved uses are uncontroversial and life-saving. Its off-label uses, particularly for cardiovascular disease, exist in a gray zone where a legitimate NIH-funded trial showed a real signal, but the evidence is not yet strong enough for mainstream adoption.

The controversy is fueled by both sides overreaching. Some conventional physicians dismiss all off-label chelation as quackery, ignoring the TACT data. Some chelation advocates oversell it as a miracle treatment for nearly everything, citing weak or nonexistent evidence.

The responsible position lies in the middle: chelation is a real medical treatment with proven applications. The TACT data for cardiovascular disease in diabetics is intriguing and may well hold up in TACT2. For other off-label uses, the evidence ranges from thin to absent. And in all cases, chelation carries real risks that require proper medical oversight.

If you are considering chelation therapy for any reason, do your homework, find a qualified provider, insist on proper monitoring, and maintain realistic expectations about what it can and cannot do.

Related Reading

• American College for Advancement in Medicine (ACAM) — Provider directory and chelation information
• TACT2 Clinical Trial Registration — Follow-up cardiovascular chelation trial
• Lamas, G.A., & Ergui, I. (2016). “Chelation therapy to treat atherosclerosis, particularly in diabetes: Is it time to reconsider?” Expert Review of Cardiovascular Therapy, 14(8), 927-938. DOI
• Flora, S.J.S., & Pachauri, V. (2010). “Chelation in metal intoxication.” International Journal of Environmental Research and Public Health, 7(7), 2745-2788. DOI

Frequently Asked Questions

What does chelation therapy treat, and does it actually work?

It is FDA-approved and works well for documented heavy-metal poisoning, including lead, iron overload, Wilson’s disease, and acute mercury or arsenic poisoning. For these uses the evidence is clear. For heart disease the data is limited to one trial, and for autism or general detox it is not supported.

How much does chelation therapy cost?

According to the article, chelation costs $100 to $300 per intravenous session. A full course typically runs 20 to 40 sessions, so a complete 40-session course costs between $4,000 and $12,000. Oral chelating agents are also available and can be more convenient since they can be taken at home.

Is chelation therapy safe, and what are the side effects and risks?

It carries real risks. Common side effects include burning at the IV site, nausea, vomiting, headache, fatigue, and a temporary drop in blood pressure. Serious risks include kidney damage and dangerously low blood calcium, which can cause arrhythmias, seizures, and death. A child died in 2005 during EDTA chelation for autism.

How is chelation therapy administered?

It is most often given intravenously, with sessions lasting 1 to 3 hours, typically once or twice per week, over a course of 20 to 40 sessions. Oral agents such as DMSA, deferasirox, deferiprone, and penicillamine are also available and can be taken conveniently at home for certain conditions.

Who is chelation therapy actually for?

It is intended for people with documented heavy-metal poisoning confirmed by validated blood or unprovoked urine testing, not provoked urine testing. The cardiovascular research studied patients aged 50 and older who had already had a heart attack. It is not an appropriate general detox or wellness treatment for healthy people.

What is EDTA, and what did the TACT trial show about it for heart disease?

EDTA is a chelating agent studied for cardiovascular disease in the TACT trial. That trial found an 18% reduction in the primary composite endpoint (p=0.035), with a 41% reduction in cardiovascular events and 43% reduction in total mortality among diabetics. However, it was a single trial with roughly 17% dropout and blinding concerns, so replication is needed.

References

1. Hauptman, M., Bruccoleri, R., & Woolf, A.D. (2019). An update on childhood lead poisoning. The Journal of Pediatrics. https://doi.org/10.1016/j.jpeds.2019.06.052” target=”_blank”>DOI
2. Flora, S.J.S., & Pachauri, V. (2019). Chelation in metal intoxication: An update. Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2019.09.016” target=”_blank”>DOI
3. Lamas, G.A., Goertz, C., Boineau, R., et al. (2013). Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: The TACT randomized trial. JAMA, 309(12), 1241-1250. https://doi.org/10.1001/jama.2013.2107” target=”_blank”>DOI
4. Escolar, E., Lamas, G.A., Mark, D.B., et al. (2014). The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the TACT. Circulation Research, 114(8), 1282-1288. https://doi.org/10.1161/CIRCRESAHA.113.301560” target=”_blank”>DOI
5. Lamas, G.A., Navas-Acien, A., Mark, D.B., & Lee, K.L. (2018). TACT2: Trial to assess chelation therapy 2. American Heart Journal. https://doi.org/10.1016/j.ahj.2018.06.007” target=”_blank”>DOI
6. Saliba, A.N., Harb, A.R., & Taher, A.T. (2019). Iron chelation therapy in transfusion-dependent thalassemia patients. Blood. https://doi.org/10.1182/blood-2018-10-876888” target=”_blank”>DOI
7. European Association for the Study of the Liver (2019). EASL clinical practice guidelines: Wilson’s disease. Journal of Hepatology. https://doi.org/10.1002/hep.30989” target=”_blank”>DOI
8. Rafati-Rahimzadeh, M., Rafati-Rahimzadeh, M., Kazemi, S., & Moghadamnia, A.A. (2019). Therapeutic options for mercury poisoning. Journal of Medical Toxicology. https://doi.org/10.1007/s13181-019-00726-x” target=”_blank”>DOI
9. Bjorklund, G., Mutter, J., & Aaseth, J. (2019). Metal chelators and neurotoxicity. Toxicology Letters. https://doi.org/10.1016/j.toxlet.2019.05.015” target=”_blank”>DOI
10. Hviid, A., Hansen, J.V., Frisch, M., & Melbye, M. (2019). Measles, mumps, rubella vaccination and autism. Annals of Internal Medicine, 170(8), 513-520. https://doi.org/10.1016/j.vaccine.2019.10.010” target=”_blank”>DOI
11. Bauer, A.Z., Kriebel, D., Herbert, M.R., et al. (2020). The role of environmental factors in autism. Pediatrics. https://doi.org/10.1542/peds.2019-1895” target=”_blank”>DOI
12. Ruha, A.M., Curry, S.C., Gerkin, R.D., et al. (2019). Urine metal testing following chelation challenge. Clinical Toxicology. https://doi.org/10.1080/15563650.2019.1582203” target=”_blank”>DOI
13. Lamas, G.A. (2015). Chelation therapy: A new look at an old treatment for heart disease, particularly in diabetes. Circulation, 131(21), e471-e479. https://doi.org/10.1161/CIR.0000000000000176” target=”_blank”>DOI
14. Tellez-Plaza, M., Jones, M.R., Dominguez-Lucas, A., et al. (2013). Cadmium exposure and clinical cardiovascular disease. Atherosclerosis, 227(1), 1-8. https://doi.org/10.1016/j.atherosclerosis.2013.01.005” target=”_blank”>DOI
15. Kim, J.J., Kim, Y.S., & Kumar, V. (2019). Heavy metal toxicity: An update with chelation therapeutic strategies. Journal of Trace Elements in Medicine and Biology. https://doi.org/10.1016/j.jtemb.2019.05.003” target=”_blank”>DOI

This article is for informational purposes only. It is not medical advice. Chelation therapy carries real risks and should only be pursued under the supervision of a qualified medical professional. Always consult your physician before beginning any new treatment.

About the medical reviewer

Dr. Bronwyn Holmes, MD, FAARFM is a physician specialising in regenerative medicine, advanced peptide therapeutics, exosome and stem cell biology, hormonal health, and longevity. Last reviewed July 5, 2026.